Ligand Pharmaceuticals Incorporated
LGND
$210.99
$3.191.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -48.32% | 142.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -48.32% | 142.43% | |||
| Cost of Revenue | -91.07% | 161.98% | |||
| Gross Profit | -36.62% | 137.57% | |||
| SG&A Expenses | -12.02% | 41.00% | |||
| Depreciation & Amortization | -0.01% | -1.95% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.42% | 61.88% | |||
| Operating Income | -62.96% | 456.56% | |||
| Income Before Tax | -59.77% | 1,157.57% | |||
| Income Tax Expenses | -49.73% | 274.28% | |||
| Earnings from Continuing Operations | -61.81% | 2,319.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.81% | 2,319.50% | |||
| EBIT | -62.96% | 456.56% | |||
| EBITDA | -55.33% | 255.07% | |||
| EPS Basic | -62.10% | 2,288.36% | |||
| Normalized Basic EPS | 101.77% | 451.44% | |||
| EPS Diluted | -62.74% | 2,266.67% | |||
| Normalized Diluted EPS | 98.41% | 439.55% | |||
| Average Basic Shares Outstanding | 0.76% | 1.30% | |||
| Average Diluted Shares Outstanding | 2.47% | 3.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||